Pfizer announces phase 3 TALAPRO-3 study of talzenna plus Xtandi significantly improves rPFS in metastatic prostate cancer: New York Friday, March 20, 2026, 09:00 Hrs [IST] Pfizer ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose ...

Clinical benefits of the talazoparib and enzalutamide combination extend to patients with both BRCA and non-BRCA homologous recombination repair gene alterations.

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...

Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved ...

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...

Amazon mollies don't need a man, and never will. A new study finds they can purge and repair genetic mutations that would otherwise plague a self-cloning species.

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer: Salt Lake City Thursday, March 19, 2026, 15:00 ...